Investing to Impact Cancer Treatment
The MI Bioresearch Board of Directors is composed of experienced venture capitalists and CRO leadership. The board works closely with company leadership to set a strategic direction designed to fulfill the company’s mission.
Stephen J. Sullivan
CRO Advisors LLC – Director and Chairman
Steve Sullivan founded CRO Advisors LLC in 2010 as a specialty consulting firm to advise CROs, their partners, and their investors as the CRO industry goes through unprecedented change.
In February 2006, Mr. Sullivan joined Harlan Laboratories, Inc. as CEO following Genstar Capital’s 2005 acquisition of controlling interest in the company and served as CEO until January 2010. Prior to Harlan, he was a senior vice president with Covance, Inc. where he managed clinical operations for three years and the central laboratory group for four years.
Prior to Covance, Mr. Sullivan was chairman and CEO of Xenometrix, Inc., a drug discovery tool company. Previously, he served in several senior management positions at Abbott Laboratories, including vice president of worldwide marketing for Abbott Diagnostics, and vice president and general manager of the Diagnostic Assay Sector. He also held senior management positions at Lyphomed, Inc., Dart and Kraft Inc., and Baxter International.
Concurrent with business assignments, Mr. Sullivan was a senior lecturer at the Kellogg Graduate School of Management at Northwestern University from 1982 to 1997. He has served on several public, private and nonprofit boards and is currently chairman of Interpace Diagnostics (NASDAQ: IDXG), a cancer diagnostics company, and non-executive chairman of the board of MI Bioresearch, chairman of Microbiology Research Associates, chairman of H2O Clinical Services, and a board member of Accel Clinical Research. Mr. Sullivan was an Infantry Company Commander in the U. S. Marine Corps and received his MBA from Rutgers University and a bachelor’s degree from the University of Dayton.
James Dougherty, MD
Arcus Ventures Fund – Director
Dr. Jim Dougherty is a co-founder and general partner of Arcus Ventures Fund (AVF), an oncology-focused venture capital fund based in New York City. AVF was founded in 2007 and invests in therapeutics, devices, diagnostics, and services related to cancer. Dr. Dougherty is a medical oncologist trained at Memorial Sloan Kettering Cancer Center, where he was also a faculty member and had the administrative role of deputy physician in chief for five years, overseeing clinical operations for the center.
Dr. Dougherty is a graduate of Georgetown University and Hershey Medical School of Penn State University and received an MBA from the Wharton School of the University of Pennsylvania.
Ridgeview Partners LLC – Director
Mark Eisenach has more than 20 years of corporate development, strategy, and executive management experience, primarily in the life sciences and high technology industries.
Mr. Eisenach is currently founder and managing director of Ridgeview Partners LLC, a corporate advisory firm based in Princeton, New Jersey, and he previously served as CEO of Acurian Inc., a pharmaceutical services company. Prior to that, he held a variety of senior executive positions at Covance Inc., one of the world’s largest and most comprehensive drug development services companies. In these roles, he led Covance’s worldwide business strategy, mergers and acquisitions, business partnerships, and global marketing efforts, serving on the company’s Global Leadership Council.
Earlier in his career, Mr. Eisenach spent eight years at the Boston Consulting Group and was a tax economist at Price Waterhouse. He received a bachelor’s degree from Harvard College and his MBA from Harvard Business School. He also holds Series 82 and Series 63 security licenses with Walter Greenblatt & Associates, Ridgeview Partners’ investment banking partner.
Beringea LLC – Director
Michael Gross is a managing director with Beringea, an equity and mezzanine debt investor in growth-oriented companies in the US and UK.
Mr. Gross is responsible for investment sourcing, deal execution, and portfolio management, with a focus on health care, technology-enabled services and sustainability. Mr. Gross serves as a board director for these Beringea portfolio companies: MI Bioresearch, D3O, Delphinus Medical Technologies, InTouch Health, Intervention Insights, Xanitos, Freeosk, Rethink, and Fiber By-Products.
Prior to joining Beringea, Mr. Gross was vice president of investment banking at P&M Corporate Finance where he led M&A transactions and capital raises for companies in the life sciences, health care, and outsourced business services sectors.
Mr. Gross is a CFA charter holder and earned a bachelor’s degree in finance from Michigan State University.
Tom Ludlam Jr.
MI Bioresearch – Director
Before joining MI Bioresearch as President and CEO, Tom Ludlam Jr. was president and CEO of Prologue Research International, Inc., a specialty oncology clinical CRO. In mid-2010, he led efforts to sell Prologue to Novella Clinical. Prior to Prologue, Mr. Ludlam was CEO of ArcLight Systems, LLC, a start-up venture in the pharmaceutical data/information marketplace. ArcLight was later sold to NDC Health.
The majority of Mr. Ludlam’s career has been in the pharmaceutical industry in senior leadership roles, including over 13 years at Bristol-Myers Squibb Corporation (BMS)—his last position as president of the Oncology Therapeutics Network (OTN), a specialty oncology drug distribution company, and, before that, six years at Ciba-Geigy where he rose from product manager to president/CEO of Geneva Generics/Cord Laboratories, a stand-alone generic drug subsidiary of Ciba-Geigy.
Baird Capital – Director
Nicole Walker joined Baird Capital’s Venture Capital team in 2013. She focuses on early-to-growth stage health care investments and has special areas of interest in devices and diagnostics for underserved conditions such as cancer, women’s health, and structural heart; pharmaceutical tools and services; and tech-enabled solutions to transform care delivery.
Ms. Walker is a member of the board of directors at Amphora Medical, Elucent Medical, MI Bioresearch, NeoChord Inc., NeuMoDx Molecular, and Strata Oncology, and a Life Science Council member for Springboard Enterprises, an accelerator program dedicated to building high-growth technology-oriented companies led by women.
Prior to joining Baird Capital, Ms. Walker was a venture investor with Abbott focusing on early stage biotech, device, and diagnostic opportunities; and Onset Ventures, a Menlo Park, California, firm that specializes in seed and early stage health care and tech service investments.
Before starting in venture, Ms. Walker served in a number of operating roles. She began her career as reliability and process engineer with Guidant’s Advanced Cardiovascular Systems division, then held a variety of roles within product design, engineering management, and marketing management including roles in commercial marketing, Asia-Pacific, for Guidant while based in Hong Kong and in strategic marketing for Abbott’s OUS discrete and continuous diabetes monitoring brands.
Ms. Walker received a bachelor’s degree in mechanical engineering from Stanford University and dual master’s degrees in business administration and engineering management from the Kellogg School of Management and the McCormick School of Engineering at Northwestern University.
Baird Capital – Observer
Dave Gregorka joined Baird Capital in 2013 and works to source, evaluate, and oversee investment opportunities in the health care sector with a particular emphasis on health care IT. He is an experienced executive and entrepreneur who has successfully taken multiple businesses from startup to commercial success. Mr. Gregorka is an active member of the Michigan entrepreneurial community, including his work as a mentor-in-residence for the University of Michigan Office of Technology Transfer.
Mr. Gregorka was previously a co-founder of HealthMedia and held various roles, including as the company’s chief financial officer and operations vice president. Following HealthMedia’s (now called J&J Health and Wellness Solutions) sale to Johnson & Johnson in 2008, Mr. Gregorka was responsible for various functions, including intellectual property, compliance, technical, and data center operations, quality assurance, customer support, and related management functions. He currently serves as a member of the Oversight Committee for the University of Michigan Translation and Commercialization for Life Sciences Program, the University of Michigan’s Monroe-Brown Pre-Seed Fund Investment Advisory Board, and the State of Michigan Advisory Board of Examiners, and he is a director for Invest Michigan. Mr. Gregorka has an MBA from the University of Michigan and a bachelor’s degree from the University of Rochester.